by Satish Pandelenghat and Manjunath Shanabag The relationship between the life sciences industry and healthcare practitioners has changed dramatically in recent years. It wasn’t that long ago that sales reps visited each practice to provide information about new products. That changed in the late 1990s and early 2000s as information became more digital. Now what […]
by Dawn Waite and Sadia Ahmed There are so many balls in the air when managing global regulatory submissions that it’s all too easy to lose sight of the bigger picture. That picture really should be focusing on the portfolio, building your regulatory intelligence and strengthening your position in the market. But the day-to-day strain […]
by Satish Nair and Manjunath Shanabag Pharmaceutical companies struggle with a complex and, often, poorly managed partner, customer and distribution network. It’s not surprising, given the makeup of most large pharma companies. Large, often disconnected product portfolios are built through discovery — both internally and externally with academia and biotech partners — and global clinical […]
by Dawn Waite Technology as an enabler for innovation and process improvement has become the catchword for most companies. Whether it’s artificial intelligence and machine learning, gaining insights from data through better analytics capabilities, or the ability to transfer data and knowledge to the cloud, life sciences companies are looking to achieve greater efficiencies and […]
by Jared Kimble The opportunity to transform the way pharmaceutical companies do business through digital technologies can be felt across the entire life cycle. One such area is labeling, which has long struggled with issues related to document ownership and control, maintaining accurate status, having a global view of the processes, reviews and approvals, and […]
Recent headlines have been full of news about major healthcare mergers and acquisitions, often involving newcomers to the industry, but also creating a convergence of traditional payer, provider and pharmaceutical benefit management companies. Here are some of the latest examples in the changing healthcare scene: CVS Health, a large pharmaceutical benefit manager, is purchasing Aetna, […]
by Jared Kimble Data is all around us. It’s created with everything we do. For the life sciences industry, this means data is being collected faster and at a greater rate than ever before. Data takes the form of structured content — from clinical trials, regulatory filings, manufacturing and marketing, drug interactions and real-world evidence […]
By Sharad Khusal A new, connected dynamic is making its way into the life sciences and healthcare industries, shifting companies from a traditionally siloed approach to an integrated 3.0 environment. Here the emphasis is on a healthy outcomes ecosystem — one that spans nontraditional players such as IT, retailers and nonprofit organizations. At the heart […]
by Sharad Khusal The life sciences business model is changing. In the past, companies typically worked with fewer partners, most often collaborating only with the physician, or indirectly, with patients. That later expanded to liaising with academia and the contract research organizations (CROs) directly affiliated with them. Today, those walls have come down and pharmaceutical […]
by Gireesh Gaonkar As a medicinal product moves from R&D into approval and manufacturing, it must deal with a complex and dispersed distribution network and a global network of manufacturing sites, some of which may be using old, noncomputer numerical control-enabled (non-CNC-enabled) machinery. Advances in technologies and the digital value chain create new pathways for […]